|
2026 Journal Article Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysisAlexander, Marliese, Itchins, Malinda, Felthun, Jonathan, Nagrial, Adnan, Brown, Lauren J., O'Byrne, Kenneth, Mersiades, Antony J., Hughes, Brett G.M., Warburton, Lydia, Kong, Benjamin Y., Moore, Melissa, Blinman, Prunella, Bowyer, Samantha, Clay, Timothy, Spelman, Tim, Pavlakis, Nick, Solomon, Benjamin J. and Kao, Steven (2026). Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis. Lung Cancer, 211 108854, 108854. doi: 10.1016/j.lungcan.2025.108854 |
|
2025 Journal Article Circulating tumour cells and circulating tumour DNA in head and neck cancer: from molecular insights to clinical impactDamodaran, Sreedevi, Weeramange, Chameera Ekanayake, Kenny, Lizbeth, Vasani, Sarju, Hughes, Brett G. M., Breik, Omar and Punyadeera, Chamindie (2025). Circulating tumour cells and circulating tumour DNA in head and neck cancer: from molecular insights to clinical impact. Cancer and Metastasis Reviews, 44 (4) 88. doi: 10.1007/s10555-025-10305-y |
|
2025 Journal Article Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancerAndreas, V., Faltys, M., Alexander, M., Rogers, J., Parakh, S., Bowyer, S., Warburton, L., Fantoni, A., Clay, T., Arulananda, S., Sullivan, I., Kao, S., Da Silva, I., Brown, L. J., Hughes, B. G.M., Itchins, M., Solomon, B. and John, T. (2025). Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer, 209 108786, 108786. doi: 10.1016/j.lungcan.2025.108786 |
|
2025 Journal Article Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the De-Squamate studyLadwa, Rahul, Lee, Jenny H., McGrath, Margaret, Cooper, Caroline, Liu, Howard, Bowman, James, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle, Clark, Jonathan R., Le, Dieu, Pauley, Marketa, Kulasinghe, Arutha, Gonzalez-Cruz, Jazmina, Porceddu, Sandro V., Hughes, Brett G.M. and Panizza, Benedict (2025). Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the De-Squamate study. Journal of Clinical Oncology, 43 (26) JCO-25-00387, 2888-2896. doi: 10.1200/jco-25-00387 |
|
2025 Journal Article Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialDingemans, Anne-Marie C., Syrigos, Konstantinos, Livi, Lorenzo, Paulus, Astrid, Kim, Sang-We, Chen, Yuanbin, Felip, Enriqueta, Griesinger, Frank, Ohashi, Kadoaki, Zalcman, Gerard, Hughes, Brett G.M., Sørensen, Jens Benn, Blais, Normand, Ferreira, Carlos G.M., Lindsay, Colin R., Dziadziuszko, Rafal, Ward, Patrick J., Obiozor, Cynthia Chinedu, Wang, Yang and Peters, Solange (2025). Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer, 207 108683, 108683-207. doi: 10.1016/j.lungcan.2025.108683 |
|
2025 Journal Article 1657P De-squamate study: Event-free survival outcomes in clinical or pathological complete respondersLadwa, R., Hughes, B.G.M., Panizza, B., Cooper, C., Liu, H., Bowman, J., Gupta, R., Cuscaden, C., Nottage, M.K., Clarke, J., McGrath, M., Porceddu, S.V. and Lee, J. (2025). 1657P De-squamate study: Event-free survival outcomes in clinical or pathological complete responders. Annals of Oncology, 36, S981-S982. doi: 10.1016/j.annonc.2025.08.2285 |
|
2025 Journal Article The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironmentTan, Chin Wee, Berrell, Naomi, Donovan, Meg L., Monkman, James, Lawler, Clara, Sadeghirad, Habib, Naei, Vahid Yaghoubi, Chen, Jinjin, Rossenbloom, Alyssa, Bonnett, Shilah, Conner, Mark, Filanoski, Brian, Kang, Christine, Beechem, Joseph M., Fraser, John F., Barnett, Catherine, Ladwa, Rahul, Hughes, Brett G. M. and Kulasinghe, Arutha (2025). The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment. NPJ Precision Oncology, 9 (1) 191. doi: 10.1038/s41698-025-00963-0 |
|
2025 Journal Article Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerUppaluri, Ravindra, Haddad, Robert I., Tao, Yungan, Le Tourneau, Christophe, Lee, Nancy Y., Westra, William, Chernock, Rebecca, Tahara, Makoto, Harrington, Kevin J., Klochikhin, Arkadiy L., Braña, Irene, Vasconcelos Alves, Gustavo, Hughes, Brett G. M., Oliva, Marc, Pinto Figueiredo Lima, Iane, Ueda, Tsutomu, Rutkowski, Tomasz, Schroeder, Ursula, Mauz, Paul-Stefan, Fuereder, Thorsten, Laban, Simon, Oridate, Nobuhiko, Popovtzer, Aron, Mach, Nicolas, Korobko, Yevhen, Costa, Diogo Alpuim, Hooda-Nehra, Anupama, Rodriguez, Cristina P., Bell, R. Bryan ... Adkins, Douglas (2025). Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. New England Journal of Medicine, 393 (1), 37-50. doi: 10.1056/nejmoa2415434 |
|
2025 Conference Publication Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)Tao, Yungan, Siu, Lillian L., Licitra, Lisa F., Burtness, Barbara, Tahara, Makoto, Rischin, Danny, Alves, Gustavo Vasconcelos, Pinto Figueiredo Lima, Iane, Hughes, Brett Gordon Maxwell, Pointreau, Yoann, Aksoy, Sercan, Laban, Simon, Greil, Richard, Burian, Martin, Hetnał, Marcin, Delord, Jean-Pierre, Kassalow, Laurent, Bidadi, Behzad, Gumuscu, Burak and Machiels, Jean-Pascal H. (2025). Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.6013 |
|
2025 Conference Publication Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 studyAdkins, Douglas, Haddad, Robert I., Tao, Yungan, Le Tourneau, Christophe, Lee, Nancy Y., Sindhu, Kunal, Chernock, Rebecca, Tahara, Makoto, Harrington, Kevin Joseph, Klochikhin, Arkadiy, Brana, Irene, Alves, Gustavo Vasconcelos, Hughes, Brett Gordon Maxwell, Oliva, Marc, Pinto Figueiredo Lima, Iane, Ueda, Tsutomu, Manschot, Cole, Benjamin, Kimberly Thomas, Bidadi, Behzad and Uppaluri, Ravindra (2025). Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.6012 |
|
2025 Conference Publication Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 studyUppaluri, Ravindra, Haddad, Robert I., Tao, Yungan, Le Tourneau, Christophe, Lee, Nancy Y., Westra, William, Chernock, Rebecca, Tahara, Makoto, Harrington, Kevin, Klochikhin, Arkadiy L., Braña, Irene, Alves, Gustavo Vasconcelos, Hughes, Brett G.M., Oliva, Marc, Figueiredo Lima, Iane Pinto, Ueda, Tsutomu, Rutkowski, Tomasz, Schroeder, Ursula, Mauz, Paul-Stefan, Fuereder, Thorsten, Laban, Simon, Oridate, Nobuhiko, Popovtzer, Aron, Mach, Nicolas, Korobko, Yevhen, Costa, Diogo Alpuim, Hooda-Nehra, Anupama, Rodriguez, Cristina P., Bell, R. Bryan ... Adkins, Douglas (2025). Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-ct001 |
|
2025 Journal Article Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyTahara, Makoto, Greil, Richard, Rischin, Danny, Harrington, Kevin J., Burtness, Barbara, de Castro, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Lin, Jianxin, Gumuscu, Burak, Lerman, Nati and Soulières, Denis (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer, 221 115395, 115395. doi: 10.1016/j.ejca.2025.115395 |
|
2025 Conference Publication Exploring PD1/PDL1 interactions and macrophage-tumor barriers in head and neck cancer: A spatial approach to immunotherapy responseNaei, Vahid Yaghoubi, Tubelleza, Rafael, Monkman, James, Sadeghirad, Habib, Donovan, Meg L., Blick, Tony, Wicher, Agata, Bodbin, Sara, Basu, Subham, Stad, Robert, Barnett, Catherine, O’Byrne, Ken, Ladwa, Rahul, Cooper, Caroline, Warkiani, Majid Ebrahimi, Hughes, Brett G.M. and Kulasinghe, Arutha (2025). Exploring PD1/PDL1 interactions and macrophage-tumor barriers in head and neck cancer: A spatial approach to immunotherapy response. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-750 |
|
2025 Conference Publication Characterising head and neck tumour microenvironment using high plex spatial omics technologies and analysesTan, Chin Wee, Berrell, Naomi, Donovan, Meg L., Monkman, James, Sadeghirad, Habib, Naei, Vahid Yaghoubi, Chen, Jinjin, Rossenbloom, Alyssa, Bonnett, Shilah, Conner, Mark, Filanoski, Brian, Kang, Christine, Beechem, Joseph M., Fraser, John F., Barnett, Catherine, Ladwa, Rahul, Hughes, Brett G. and Kulasinghe, Arutha (2025). Characterising head and neck tumour microenvironment using high plex spatial omics technologies and analyses. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-175 |
|
2025 Conference Publication 2D and 3D spatial characterisation of tertiary lymphoid structures in head and neck cancer patients receiving immune checkpoint blockade therapyDonovan, Meg L., Sadeghirad, Habib, Berrell, Naomi, Monkman, James, Naei, Vahid Yaghoubi, Tan, Chin Wee, Yunis, Joseph, West, Zoe, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G., Da Gama Duarte, Jessica and Kulasinghe, Arutha (2025). 2D and 3D spatial characterisation of tertiary lymphoid structures in head and neck cancer patients receiving immune checkpoint blockade therapy. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-5252 |
|
2025 Journal Article Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort studyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort study. Annals of Surgical Oncology, 32 (4), 2725-2731. doi: 10.1245/s10434-024-16854-w |
|
2025 Journal Article ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort StudyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort Study. Annals of Surgical Oncology, 32 (5), 3485-3486. doi: 10.1245/s10434-025-16995-6 |
|
2025 Journal Article Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy responseNaei, Vahid Yaghoubi, Tubelleza, Rafael, Monkman, James, Sadeghirad, Habib, Donovan, Meg L., Blick, Tony, Wicher, Agata, Bodbin, Sara, Viratham, Amelie, Stad, Robert, Basu, Subham, Cooper, Caroline, Barnett, Catherine, O’Byrne, Ken, Ladwa, Rahul, Warkiani, Majid Ebrahimi, Hughes, Brett G. M. and Kulasinghe, Arutha (2025). Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response. Journal of Translational Medicine, 23 (1) 177, 1-15. doi: 10.1186/s12967-025-06186-y |
|
2025 Journal Article Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE)Lee, Chee Khoon, Liao, Bin-Chi, Subramaniam, Shalini, Chiu, Chao-Hua, Mersiades, Antony J., Ho, Chao-Chi, Brown, Chris, Lai, Chun-Liang, Hughes, Brett G. M., Yang, Tsung-Ying, O'Byrne, Ken, Luo, Yung-Hung, Yip, Sonia, Ho, Ching-Liang, Bray, Victoria, Su, Wu-Chou, Moore, Melissa, Feng, Wei-Lien, Bai, Ya-Ying, Ford, Kate, Cummins, Michelle M., Stockler, Martin R., Solomon, Benjamin J., John, Thomas and Chih-Hsin Yang, James (2025). Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE). JTO Clinical and Research Reports, 6 (2) 100771, 100771. doi: 10.1016/j.jtocrr.2024.100771 |
|
2025 Journal Article Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyChin, Wee Loong, Cook, Alistair M., Chee, Jonathan, Principe, Nicola, Hoang, Tracy S., Kidman, Joel, Hmon, Khaing P.W., Yeow, Yen, Jones, Matthew E., Hou, Rui, Denisenko, Elena, McDonnell, Alison M., Hon, Chung-Chau, Moody, Jonathan, Anderson, Denise, Yip, Sonia, Cummins, Michelle M., Stockler, Martin R., Kok, Peey-Sei, Brown, Chris, John, Thomas, Kao, Steven C.-H., Karikios, Deme J., O'Byrne, Kenneth J., Hughes, Brett G.M., Lake, Richard A., Forrest, Alistair R.R., Nowak, Anna K., Lassmann, Timo and Lesterhuis, W. Joost (2025). Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell Reports Medicine, 6 (1) 101882, 1-18. doi: 10.1016/j.xcrm.2024.101882 |
